Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

ClinicalTrials.gov ID: NCT03917472

Public ClinicalTrials.gov record NCT03917472. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (KINGFISHER)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study was to evaluate the efficacy and safety of brolucizumab vs. aflibercept in the treatment of patients with visual impairment due to diabetic macular edema (DME).

Study identification

NCT ID
NCT03917472
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
517 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 17, 2019 (Actual)
Primary completion
Mar 24, 2021 (Actual)
Completion
Mar 24, 2021 (Actual)
Last update posted
Aug 12, 2022

2019 – 2021

United States locations

U.S. sites
74
U.S. states
26
U.S. cities
69
Facility City State ZIP Site status
Novartis Investigative Site Phoenix Arizona 85016 —
Novartis Investigative Site Phoenix Arizona 85053 —
Novartis Investigative Site Tucson Arizona 85704-5614 —
Novartis Investigative Site Beverly Hills California 90211 —
Novartis Investigative Site Campbell California 95008 —
Novartis Investigative Site Fresno California 93720 —
Novartis Investigative Site Huntington Beach California 92647 —
Novartis Investigative Site Loma Linda California 92354 —
Novartis Investigative Site Mountain View California 94040 —
Novartis Investigative Site Oakland California 94609 —
Novartis Investigative Site Pasadena California 91107 —
Novartis Investigative Site Poway California 92064 —
Novartis Investigative Site Rancho Cordova California 95670 —
Novartis Investigative Site Redlands California 92374 —
Novartis Investigative Site Riverside California 92505 —
Novartis Investigative Site Sacramento California 95817 —
Novartis Investigative Site Sacramento California 95841 —
Novartis Investigative Site San Francisco California 94107 —
Novartis Investigative Site Santa Ana California 92705 —
Novartis Investigative Site Santa Barbara California 93103 —
Novartis Investigative Site Torrance California 90509-2910 —
Novartis Investigative Site Ventura California 93003 —
Novartis Investigative Site Altamonte Springs Florida 32701 —
Novartis Investigative Site Deerfield Beach Florida 33064 —
Novartis Investigative Site Fort Lauderdale Florida 33309 —
Novartis Investigative Site Fort Myers Florida 33912-7125 —
Novartis Investigative Site Orlando Florida 32804 —
Novartis Investigative Site Pinellas Park Florida 33782 —
Novartis Investigative Site St. Petersburg Florida 33711 —
Novartis Investigative Site Tampa Florida 33609 —
Novartis Investigative Site Atlanta Georgia 30342 —
Novartis Investigative Site Marietta Georgia 30060 —
Novartis Investigative Site ‘Aiea Hawaii 96701 —
Novartis Investigative Site Bloomington Illinois 61704 —
Novartis Investigative Site Oak Forest Illinois 60452 —
Novartis Investigative Site Springfield Illinois 62704 —
Novartis Investigative Site Indianapolis Indiana 46280 —
Novartis Investigative Site New Albany Indiana 47150 —
Novartis Investigative Site West Des Moines Iowa 50266 —
Novartis Investigative Site Leawood Kansas 66211 —
Novartis Investigative Site Lenexa Kansas 66215 —
Novartis Investigative Site Hagerstown Maryland 21740 —
Novartis Investigative Site Boston Massachusetts 02114 —
Novartis Investigative Site Royal Oak Michigan 48073 —
Novartis Investigative Site Minneapolis Minnesota 55435 —
Novartis Investigative Site Kansas City Missouri 64133 —
Novartis Investigative Site Reno Nevada 89502 —
Novartis Investigative Site Bloomfield New Jersey 07003 —
Novartis Investigative Site Teaneck New Jersey 07666 —
Novartis Investigative Site Rochester New York 14620 —
Novartis Investigative Site Hickory North Carolina 28602 —
Novartis Investigative Site Southern Pines North Carolina 28387 —
Novartis Investigative Site Cleveland Ohio 44122 —
Novartis Investigative Site Columbus Ohio 43210 —
Novartis Investigative Site Dublin Ohio 43016 —
Novartis Investigative Site Eugene Oregon 97401 —
Novartis Investigative Site Kingston Pennsylvania 95403 —
Novartis Investigative Site Chattanooga Tennessee 37421 —
Novartis Investigative Site Germantown Tennessee 38138 —
Novartis Investigative Site Abilene Texas 79606 —
Novartis Investigative Site Austin Texas 78705 —
Novartis Investigative Site Austin Texas 78731 —
Novartis Investigative Site Austin Texas 78750 —
Novartis Investigative Site Bellaire Texas 77401 —
Novartis Investigative Site Dallas Texas 75231 —
Novartis Investigative Site Fort Worth Texas 76104 —
Novartis Investigative Site Harlingen Texas 78550 —
Novartis Investigative Site Houston Texas 77025 —
Novartis Investigative Site Houston Texas 77030 —
Novartis Investigative Site San Antonio Texas 78240 —
Novartis Investigative Site Southlake Texas 76092 —
Novartis Investigative Site Norfolk Virginia 23502 —
Novartis Investigative Site Morgantown West Virginia 26506 —
Novartis Investigative Site Madison Wisconsin 53705-3611 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03917472, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 12, 2022 · Synced Oct 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT03917472 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →